Increased risk of deep neck infection among HIV-infected patients in the era of highly active antiretroviral therapy—a population-based follow-up study

BMC Infectious Diseases

Jhi-Joung Wang⁴  Ching-Feng Lien²  Chih-Sheng Lin¹  Yung-Song Lin²  Shih-Feng Weng³  Ching-Feng Liu¹ 

[1] Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan;Department of Otolaryngology, Chi Mei Medical Center, Tainan, Taiwan;Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy and Science, Tainan, Taiwan;Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan

关键词: Highly active antiretroviral therapy;    HIV;    Deep neck infection;   

Others  :  1148860
DOI  :  10.1186/1471-2334-13-183

 received in 2012-12-02, accepted in 2013-04-14,  发布年份 2013

【 摘 要 】

Background

Deep neck infections (DNIs) in HIV-infected patients often produce severe complications, even death. Data on the incidence rates and risks of DNI among HIV-infected patients are scarce, particularly with the widespread use of highly active antiretroviral therapy (HAART). We evaluated the incidence rates and risks for DNI among HIV-infected patients and observed the long-term trends.

Methods

A total of 9888 new HIV-infected patients diagnosed in 2001–2007 were included and matched with 49440 randomly selected subjects. The HIV-infected subjects were offered free access to HAART. All subjects were traced until December 2009. A Kaplan-Meier analysis generated the cumulative DNI incidence rate. The adjusted hazard ratio was computed using Cox proportional hazard regressions.

Results

From the HIV-infected and comparison cohorts, 222 individuals (57.01 cases per 10000 person-years) and 735 individuals (35.54 cases per 10000 person-years) developed DNI, respectively. The log rank test indicated that patients with HIV had a significantly higher 8-year incidence rate of DNI than the control group (P < 0.0001). The adjusted hazard ratio for developing DNI after an HIV attack during the mean 3.94 years follow-up period was 1.59. The incidence rate and relative risk of DNI were 74.58 (per 10000 person-years) and 2.05 (P < 0.0001). Both figures were highest in the first follow-up year and decreased year-by-year thereafter.

Conclusion

The risk of developing DNI is significantly elevated among HIV-infected patients, even with free access to HAART. Additional research is needed to examine the role of HAART in reducing the risk.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Fauci AS, Eugene B, Kasper DL, Hauser SL, Longo DL, Larry Jameson J, Joseph L: Harrison’s Principles of Internal Medicine. 17th edition. New York: McGraw-Hill; 2008:213. 1200
• [2]Vieira F, Allen SM, Stocks RM, Thompson JW: Deep Neck Infection. Otolaryngol Clin North Am 2008, 41:459-483.
• [3]Huang TT, Liu TC, Chen PR, Tseng FY, Yeh TH, Chen YS: Deep neck infection: analysis of 185 cases. Head Neck 2004, 26:854-860.
• [4]Hasegawa J, Hidaka H, Tateda M, Kudo T, Sagai S, Miyazaki M, Kataqiri K, Nakanome A, Ishida E, Ozawa D, Kobayashi T: An analysis of clinical risk factors of deep neck infection. Auris Nasus Larynx 2011, 38:101-107.
• [5]Daramola OO, Flanagan CE, Maisel RH, Odland RM: Diagnosis and treatment of deep neck space abscesses. Otolarngol Head Neck Surg 2009, 141:123-130.
• [6]Nour YA, Hassan MH, Gaafar A, Eldaly A: Deep Neck Infections of Congenital Causes. Otolaryngol Head Neck Surg 2011, 144:365-371.
• [7]Cabrera CE, Deutsch ES, Eppes S, Lawless S, Cook S, O’Reilly RC, Reilly JS: Increased incidence of head and neck abscesses in children. Otolaryngol Head Neck Surg 2007, 136:176-181.
• [8]Marioni G, Castegnaro E, Staffieri C, Rinaldi R, Giacomeli L, Boninseqna M, Bertolin A, Staffieri A: Deep neck infection in elderly patients: a single institution experience (2000–2004). Aging Clin Exp Res 2006, 18:127-132.
• [9]Srivanitchapoom C, Sittitrai P, Pattarasakulchai T, Tananuvat R: Deep neck infection in Northern Thailand. Eur Arch Otorhinolaryngol 2012, 269:241-246. Epub 2011 Mar 24
• [10]Mandell GL, Bennett JE, Raphael D: Principles and Practice of Infectious Disease. 6th edition. Philadelphia: Elsevier Churchill Livingstone; 2005:1570.
• [11]Feikin DR, Feldman C, Schuchat A, Janoff EN: Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004, 4:445-455.
• [12]Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski A, Helm EB: Changing incidence of AIDS—defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
• [13]Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, Lang JM, Massip P, Mechali D, Leclercq P, Modai J, Portier H: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-105.
• [14]Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
• [15]Deeks SG, Smith M, Holodniy A, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. J Am Med Assoc 1997, 277:145-153.
• [16]Bailey BJ, Johnson JT, Newlands SD: Head and Neck Surgery—Otolaryngology 4th Ed. Philadelphia: Lippincott Williams & Wilkins; 2006:665-681.
• [17]Seaberg EC, Wiley D, Martinez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP: Cancer incidence in the multicenter AIDS cohort study before and during the HAART Era: 1984 to 2007. Cancer 2010, 116(23):5507-5516.
• [18]Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biqqar RJ: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20:1645-1654.
• [19]Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society–USA Panel. JAMA 2000, 283:381-390.